Health Canada
www.hc-sc.gc.ca
Common menu bar links
Institutional links
Discussion Papers
This content was archived on June 24, 2013.
Archived Content
Information identified as archived on the Web is for reference, research or recordkeeping purposes. It has not been altered or updated after the date of archiving. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats on the "Contact Us" page.
The online consultation is now closed. The content found on this page is a snapshot of the live consultation as it was presented to the public and contains the content that was open for submissions during the consultation period.
Each discussion paper explores one issue that has been identified as integral to the development of a new drug licensing system. The papers examine some of the challenges that must be answered by a modern drug framework. They do not attempt to provide solutions, which will come as a result of a consultation with the stakeholders.
The discussion papers have been themed by their general topics. Each paper contains questions for stakeholders and a request form that will be submitted directly to Health Canada. The feedback on these questions will inform the development of the new drug licensing framework. The deadline for submitting comments on these discussion papers is October 31, 2008.
In addition to the questions in each discussion paper, stakeholders can provide general feedback by submitting comments directly to the Progressive Licensing Project through their dedicated e-mail address: progressive_licensing@hc-sc.gc.ca.
- Overarching Issues
- Initial Market Authorization
- Exceptional Circumstances
- Drug Labelling
- Conditions Associated with Market Authorization
- Post-market Authorization
- Risk Management and Risk Communication
- Graduated System of Enforcement and Compliance
Contact information for the Progressive Licensing Project.
